BC003965 Activators
BC003267 activators encompass a diverse array of chemical compounds that indirectly enhance the functional activity of BC003267 through modulation of various signaling pathways. Forskolin and FSK, both adenylyl cyclase activators, along with IBMX and Rolipram, phosphodiesterase inhibitors, raise intracellular cAMP levels, potentially enhancingBC003267 activators through elevated cAMP in the case of BC003267 being responsive to such signaling. PMA, a potent PKC activator, mimics the natural ligand DAG, potentially leading to an enhancement of BC003267's activity through PKC pathway modulation. Furthermore, Sphingosine-1-phosphate could influence BC003267 by engaging with sphingosine-1-phosphate receptors and modulating subsequent intracellular signaling cascades. Similarly, the calcium ionophore A23187 and the SERCA pump inhibitor Thapsigargin both raise cytosolic calcium levels, potentially enhancing BC003267 activity if it is calcium-responsive.
The activity of BC003267 may also be indirectly augmented by compounds that affect tyrosine kinase signaling and the PI3K/AKT pathway. Genistein, a tyrosine kinase inhibitor, could remove competitive inhibition, allowing pathways involving BC003267 to become more predominant. This is complemented by LY294002, a PI3K inhibitor, which could shift the cellular signaling balance to favor BC003267 activation if it lies downstream of PI3K/AKT. In the realm of the MAPK pathway, U0126 and SB203580, inhibitors of MEK1/2 and p38 MAPK respectively, may also indirectly promote BC003267 activity. By inhibiting key kinases in the MAPK pathway, these compounds could redirect signaling through alternate routes that activate BC003267, assuming it is a part of or regulated by MAPK-dependent processes. Collectively, these activators work through intricate cellular signaling networks, each potentially playing a role in the amplification of BC003267's functional activities within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator. It mimics diacylglycerol (DAG), a physiological activator of PKC. By activating PKC, PMA indirectly enhances the activity of BC003267 if BC003267 is part of a cellular process modulated by PKC signaling. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
This lipid signaling molecule activates sphingosine-1-phosphate receptors, which can modulate various intracellular signaling pathways. If BC003267 is linked to pathways affected by such receptors, sphingosine-1-phosphate could indirectly enhance the activity of BC003267 through these pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents cAMP degradation. It can increase the activity of BC003267 by elevating cAMP levels if BC003267 is modulated by cAMP-dependent pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels within the cell. If BC003267's activity is cAMP-dependent, rolipram may enhance this activity by preventing cAMP degradation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels. If BC003267 is activated by calcium-dependent signaling, A23187 could serve as an indirect activator by increasing calcium influx. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that raises cytosolic calcium levels. It may enhance the activity of BC003267 if BC003267 is calcium-responsive, by elevating intracellular calcium and activating calcium-dependent signaling pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. It may enhance the activity of BC003267 by inhibiting competing tyrosine kinase pathways, thus indirectly shifting signaling towards pathways in which BC003267 is involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can affect the downstream AKT signaling pathway. If BC003267 is part of or regulated by the PI3K/AKT pathway, LY294002 may enhance the activity of BC003267 through indirect modulation of this signaling axis. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes in the MAPK pathway. By inhibiting MEK1/2, U0126 may indirectly enhance the activity of BC003267 if BC003267 activity is modulated through MAPK signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. It may enhance BC003267 activity by inhibiting p38 MAPK, which could shift the balance of cellular signaling towards pathways that activate BC003267. | ||||||